Lumen Technologies, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Louisiana against Lumen Technologies, Inc.

Upcoming Lead Plaintiff Deadline is November 14, 2023

NEW YORK, Sept. 26, 2023 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Lumen Technologies, Inc. ("Lumen" or the "Company") (NYSE: LUMN) securities between March 11, 2019 and July 14, 2023, inclusive (the "Class Period").

All investors who purchased shares and incurred losses are advised to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.whafh.com.

If you have incurred losses, you may, no later than November 14, 2023, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights.

PLEASE CLICK HERE TO PROVIDE CONTACT AND TRANSACTION INFORMATION 

On July 9, 2023, the Wall Street Journal reported that over 2,000 lead-covered cables used by various telecommunication companies were degrading and leaching into soil and groundwater, posing a significant public health risk. On this news, Lumen's stock price fell $0.13, or 5.9%, to close at $2.06 per share on
July 10, 2023, thereby injuring investors.

Then, on July 11, 2023, the Wall Street Journal published another article reporting that "[l]awmakers are demanding that telecom firms act to ensure that Americans are safe after [an] investigation revealed that phone companies have left behind a network of cables covered in toxic lead, tainting water and soil in some locations." Another article was published the following day detailing Lumen's ownership of lead-covered cables previously owned by AT&T, as well as evidence suggesting that Lumen's workers still face exposure to lead. On this news, Lumen's stock price fell $0.03, or 1.5%, to close at $2.04 per share on July 12, 2023.

Subsequently, on July 14, 2023, in a report published by Seeking Alpha, a J.P. Morgan analyst stated that Lumen likely has "exposure to potential copper [cable] lead sheathing liability." On this news, Lumen's stock price fell $0.21, or 10.2%, to close at $1.85 per share on July 14, 2023. Also on July 14, 2023, after the market closed, the Wall Street Journal published an article regarding Lumen's exposure to liabilities related to its lead-sheathed cables, stating that, after AT&T, Verizon and Lumen would have
the most lead-covered cables to remove. On this news, Lumen's stock price fell $0.15, or 8.1%, to close at $1.70 per share on July 17, 2023.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735 or via e-mail at [email protected].

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

the class action filed on behalf of investors who
purchased or otherwise acquired Integra LifeSciences Holdings Corporation
("Integra" or the "Company") (NASDAQ: IART) common stock between March 11,
2019 and May 22, 2023, inclusive (the "Class Period").

If you suffered a loss on your Integra investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at //www.glancylaw.com/cases/Integra-LifeSciences-Holdings-Corporation/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On April 26, 2023, Integra announced that it had paused production at its 

Boston Facility and disclosed declining operation margins for the quarter and flat revenue growth projections, which the Company attributed to the manufacturing pause. On this news, Integra's stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.

Then, on May 23, 2023, Integra disclosed that it had initiated a recall of its SurgiMend, PriMatrix, Revize, and TissueMend products manufactured at its Boston facility as far back as March 1, 2018. The Company attributed the recall to a finding that products may have been distributed with higher levels of endotoxins than permitted by the product specifications. As a result, the Company expects to write off approximately $22 million in inventory. On this news, Integra's stock price fell $10.24, or 20.2%, to close at $40.48 per
share on May 23, 2023, thereby injuring investors further.

SOURCE Wolf Haldenstein Adler Freeman & Herz LLP